3results about How to "Effective immune response" patented technology

This invention discloses a porcine reproductive and respiratory syndrome virus (PRRSV) mRNA molecule and its applications. Four mRNA vaccines, GP35m-LNP, GP45m-LNP, GP345m-LNP, and GP2345m-LNP, were designed by combining the NADC30-like structural proteins GP2a, GP3, GP4, and GP5 of the PRRSV FJ1402 strain. Mouse experiments showed that GP345m-LNP induced both strong humoral and cellular immune responses, followed by GP2345m-LNP, with better efficacy than the inactivated vaccine (which only induced humoral immunity). After immunization, challenge with the PRRSV FJ1402 strain resulted in significantly reduced viral load in the blood and lungs of the GP345m-LNP group, with significantly less pathological damage to the lungs. The immunization effect was superior to the inactivated vaccine group, demonstrating promising application prospects.

This invention relates to the field of animal immunology, and more particularly to an antigen that enhances the immune response to Newcastle disease virus (NDV), its preparation method, and its application. The antigen is a fusion protein obtained by expressing the Ii-key-F-Fc recombinant vector using engineered bacteria, named the Ii-key-F-Fc fusion protein. The Ii-key-F-Fc recombinant vector is obtained by splicing three major antigenic epitope fragments from the NDV F protein and then tandemly connecting them with chicken IgY Fc and Ii-key. This invention constructs the pCold-TF-Ii-key-F-Fc prokaryotic expression plasmid by tandemly connecting the novel chicken vector Ii-key-Fc with the F antigenic epitope, and then expresses the fusion protein using an E. coli expression system to obtain a new antigen that enhances the immune response in poultry. This provides a new approach for developing a novel NDV vaccine and a new strategy for improving the immune response of subunit vaccines in poultry.

This invention belongs to the field of biomedical technology, specifically relating to a metal-organic framework material for chelating α-nucleotides, its preparation method, and its application in antitumor drugs. The preparation method of the metal-organic framework material involves dissolving ferric chloride tetrahydrate and 2,5-dihydroxy-1,4-benzenediacarboxylic acid in an organic solvent at a molar ratio of 2:3, and reacting at 105°C for 24 hours. The key to this invention is that the metal-organic framework material serves as a novel... 223 The Ra chelation platform can achieve [the desired effect] without relying on traditional chelation mechanisms. 223 The efficient capture and stable loading of Ra effectively solves the chelation problem caused by the intrinsic properties of Ra²⁺ ions, and improves... 223 Ra radiopharmaceuticals offer stability and targeting capabilities, and significantly reduce the risk of radiation exposure to non-target organs.